0000000000143107

AUTHOR

Emilio Barbera-guillem

showing 3 related works from this author

First results for resetting the antitumor immune response by immune corrective surgery in colon cancer.

1998

BACKGROUND: A critical step for cancer recurrence is the failure of the cellular immune response. It is suspected that chronic humoral immune responses against some tumor-associated antigens (TAA) can contribute to that failure. METHODS: In this study, we tested the ability of an immune corrective surgical procedure to prevent recurrences of colon cancer in stages I, II, and III. Radiolabeled anti-TAG antibodies injected intravenously become concentrated on TAG-72 immune complexes presented by follicular dendritic cells, which are responsible for the persistent humoral response against TAG-72 TAA. Using a hand-held gamma probe, we can intraoperatively detect and remove lymph nodes involved …

Oncologymedicine.medical_specialtyColorectal cancerAntibodies NeoplasmImmune systemAntigenAntigens NeoplasmInternal medicineCarcinomamedicineHumansProspective StudiesLymph nodeNeoplasm StagingAntigen PresentationbiologyFollicular dendritic cellsbusiness.industryGeneral Medicinemedicine.diseasePrognosisSurvival Analysismedicine.anatomical_structureTreatment OutcomeRadioimmunodetectionImmunologyAntibody FormationColonic Neoplasmsbiology.proteinLymph Node ExcisionSurgeryLymphImmunotherapyLymph NodesAntibodyNeoplasm Recurrence LocalbusinessAmerican journal of surgery
researchProduct

The addition of interleukin-2 to cyclophosphamide therapy can facilitate tumor growth of B16 melanoma.

1995

The role of interleukin-2 (IL-2) on tumor growth of B16F10 melanoma cells was assessed in two sets of mice with different immune status: normal (immunocompetent) mice and immunodeficient mice. The two sets of animals were treated with cyclophosphamide (CY) or IL-2 alone or with a combined therapy of CY+IL-2. On days 6 and 10 after tumor cell injection, we evaluated the incidence of hepatic B16 melanoma metastases and the percentage of hepatic volume occupied by metastatic tissue. We observed that the CY alone (300 mg/kg, days 3 and 8 post-tumoral inoculation) significantly reduced tumor growth in all treated mice; however, CY proved more effective in normal recipients than in immunodeficien…

Interleukin 2Cancer ResearchPathologymedicine.medical_specialtyCyclophosphamideRatónmedicine.medical_treatmentImmunologyMelanoma ExperimentalInjectionsAndrologychemistry.chemical_compoundImmunocompromised HostMiceIn vivomedicineImmunology and AllergyAnimalsImmunologic FactorsDrug InteractionsCyclophosphamideChemotherapybusiness.industryLiver NeoplasmsReceptors Interleukin-2Combined Modality TherapyNitrogen mustardNeoplasm ProteinsMice Inbred C57BLCytokineOncologychemistryToxicityInterleukin-2FemalebusinessImmunocompetenceNeoplasm TransplantationSpleenWhole-Body Irradiationmedicine.drugCancer immunology, immunotherapy : CII
researchProduct

Cancer-cell traffic in the liver. I. Growth kinetics of cancer cells after portal-vein delivery

1992

Following the intrasplenic injection of B16F10 melanoma cells into mice, at first single cells, and later multicellular tumor foci were observed at different times in the liver. Cell numbers and tumor volumes were determined over the next 12 days, by confocal microscopy of thick liver sections. Fifteen minutes after injection, approximately 20% of the melanoma cells were identified in the liver microvasculature; after 48 hr, only 0.68% of these retained morphologic integrity; by 5 days only 0.13% of the originally detected cells incorporated BUdR; and, by 12 days, these subsequently grew into tumor nodules. Tumor volume changes with time were not exponential and, following a non-replicative…

Cancer ResearchPathologymedicine.medical_specialtyTime FactorsPopulationMelanoma ExperimentalMetastasisMiceMesenteric VeinsParenchymaAnimalsMedicineeducationeducation.field_of_studyPortal Veinbusiness.industryCell growthMelanomaLiver Neoplasmsmedicine.diseaseExtravasationMice Inbred C57BLTransplantationOncologySplenic VeinInjections IntravenousCancer cellFemalebusinessCell DivisionNeoplasm TransplantationInternational Journal of Cancer
researchProduct